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Summary
Mouse IgG subclasses display a hierarchy of in vivo
activities, with IgG2a and IgG2b showing the greatest
protective and pathogenic properties. These enhanced
activities result, in part, from their ability to bind to a
novel,  chain-dependent, activating IgG Fc receptor,
FcRIV. FcRIV maps in the 75 kb genomic interval
between FcRII and FcRIII; its expression is re-
stricted to myeloid lineage cells, and it binds to IgG2a
and IgG2b with intermediate affinity. No binding to
IgG1 or IgG3 was observed. Blocking FcRIV binding
to pathogenic anti-platelet antibodies is sufficient to
protect mice from antibody-induced thrombocyto-
penia. Thus, the FcR system has evolved distinct ac-
tivation receptors displaying selectivity for IgG sub-
classes, with IgG1 antibodies exclusively dependent
on FcRIII, whereas IgG2a and IgG2b show preferen-
tial dependence on FcRIV activation. These distinct
binding affinities for the IgG subclasses to FcRs ac-
count for their differential protective and pathogenic
activities in vivo.
Introduction
Fc receptors for IgG couple innate and adaptive immu-
nity through their ability to activate effector cells by an-
tibody-antigen complexes and opsonized target cells.
Two broad classes of these receptors have been de-
scribed: those that activate effector cell responses and
those that inhibit those responses (Ravetch, 2003). Ac-
tivation receptors such as FcγRI and FcγRIII upon
crosslinking by IgG transduce signals through immu-
noreceptor tyrosine-based activation motif (ITAM) se-
quences, usually found on the common γ chain subunit.
Activation responses are dependent on the sequential
activation of members of the src and syk kinase fami-
lies, resulting in the recruitment of potent signaling
molecules such as PI3kinase and protein kinase C, for
example. Inhibitory signals are transduced upon co-
crosslinking of the inhibitory FcγRIIB receptor to an
ITAM-containing receptor. Phosphorylation of an immu-
noreceptor tyrosine-based inhibitory motif (ITIM) se-
quence found in the cytoplasmic domain results in the
recruitment of the SH2-containing inositol polyphos-
phate phosphatase (SHIP) and the hydrolysis of PI3K*Correspondence: ravetch@rockefeller.edu
2 These authors contributed equally to this work.
3 Present address: The Pasteur Institute, 25 rue Dr. Roux, 75015
Paris, France.products such as PIP3, resulting in the termination of
ITAM-initiated activation (Bolland and Ravetch, 1999).
Coexpression of activation and inhibitory FcRs is a gen-
eral property of effector cells such as macrophages, neu-
trophils, and mast cells and will determine whether an
IgG-initiated response results in downstream effector
cell coupling (Clynes et al., 1999). Similarly, the ability of
immune complexes (ICs) to convert immature dendritic
cells into cells capable of stimulating naive T cells is
also determined by the balance between activation and
inhibitory FcγRs (Kalergis and Ravetch, 2002; Dho-
dapkar et al., 2005). Thus, the threshold for cellular acti-
vation by ICs is determined by the relative ratios of
these opposing Fc receptor molecules.
In the mouse and in man, low-affinity activation and
inhibitory receptors have been studied most exten-
sively for the IgG1 subclass. Mice express a single acti-
vation FcR for IgG1, FcγRIII, and a single inhibitory re-
ceptor for this subclass, FcγRIIB. In vivo disruption of
each of these genes results in attenuation or enhance-
ment, respectively, of IgG1-mediated inflammatory re-
sponses (Takai et al., 1994, 1996; Hazenbos et al., 1996,
1998; Meyer et al., 1998; Wernersson et al., 1999). As
was found for IgG1, IgG2a and IgG2b are also depen-
dent on FcR expression for their ability to mediate ef-
fector responses such as ADCC, clearance of opson-
ized particles, or triggering release of inflammatory
mediators (Clynes et al., 1998, 2000; Fossati-Jimack et
al., 2000; Uchida et al., 2004). In common with IgG1,
mice deficient in the FcR-common γ chain were equally
unable to mediate effector responses to IgG2a or IgG2b
antibodies in models of immune thrombocytopenia,
IgG-mediated RBC or B cell depletion, tumor clear-
ance, and the reverse passive Arthus reactions (Takai
et al., 1994; Sylvestre and Ravetch, 1994; Clynes and
Ravetch, 1995; Clynes et al., 2000; Samuelsson et al.,
2001). Surprisingly, however, when IgG2a- and IgG2b-
mediated responses were studied in mice deficient for
the α subunit, responsible for IgG binding, for the
known activation IgG FcγRs, i.e., FcγRI or FcγRIII, only
partial or no reduction was observed in the ability of
IgG2a and IgG2b antibodies to trigger effector cell re-
sponses (Meyer et al., 1998; Hazenbos et al., 1998; Fos-
sati-Jimack et al., 2000; Barnes et al., 2002; Ioan-Facsi-
nay et al., 2002; Uchida et al., 2004). These results
suggested that other γ chain-dependent FcγRs α sub-
units might be involved in the in vivo activity of these
subclasses of antibodies.
To identify a mouse Fc receptor α subunit with speci-
ficity for IgG2a and IgG2b, we turned to the recently
described family of Fc receptor homologs (FcRHs)
identified through homology searching of the mouse
and human genomes (Davis et al., 2002). These genes
share a genomic structure and sequence similarity to
the classical FcR genes and are tightly linked to the
FcR genes on chromosome 1 in man and 1 and 3 in
the mouse. The biological function of these molecules,
such as their ligand specificity is, as yet, unknown. One
such gene, called FcRL3 or CD16-2, showed 63% se-
quence identity to the human FcγRIII α chain gene, with
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42a two-domain structure similar to those found for the r
glow-affinity FcγRII and FcγRIII genes (Davis et al., 2002;
Mechetina et al., 2002). Northern blot analysis demon- e
astrated transcripts for this gene in hematopoeitic or-
gans such as the spleen, liver, and bone marrow. The m
Fmouse genome consortium mapping placed the gene
on mouse chromosome 1, adjacent to the FcγRII and t
tFcγRIII genes (Waterston et al., 2002). However, evi-
dence for IgG binding, protein expression, or biological R
gfunction was lacking. As described below, this gene
has now been identified the α subunit of a novel IgG2a, p
gIgG2b FcγR, whose biological properties define it as an
authentic activation IgG FcR accounting for the in vivo p
activities of IgG2a and IgG2b antibodies. We have des-
ignated this mouse IgG Fc receptor mFcγRIV, in accor- S
dance with the convention established in 1991 (Ra-
T
vetch and Kinet, 1991) and in conformity with the World
m
Health Organization nomenclature standards (World
l
Health Organization, 1994).
p
t
tResults
2
mGene Mapping and Genomic
Organization of FcRIV d
FPrevious reports have linked FcγRIV (FcγRL3, CD16-2)
to the mouse low-affinity FcγRIIB and FcγRIII genes t
obased on the alignments generated by the genome
consortium. These linkages placed the FcγRIV gene either c
Fcentromeric to FcγRIIB or telomeric to FcγRIII (Davis
et al., 2002; Mechetina et al., 2002). To determine the 2
(position of the FcγRIV gene, we isolated a series of
overlapping bacterial artificial chromosome (BAC) c
Fclones from both the 129 and C57BL/6 strains that span
the FcγRII–FcγRIII locus, as shown in Figure 1A. Re- F
cstriction mapping and sequence analysis of these
clones established that FcγRIV mapped in the in- a
γtergenic interval between FcγRII and FcγRIII. Fine struc-
ture mapping of the FcγRIV gene, shown in Figure 1B, sFigure 1. Genomic Organization of FcγR
Genes on Mouse Chromosome 1
(A) Schematic representation of the mouse
FcγRIV gene in its genomic context. Filled
boxes represent genes, and arrows indicate
the direction of transcription. Representative
restriction sites are indicated. The scale indi-
cates the position of the genes on chromo-
some 1 according to the ensembl database
in mega base pairs (Mbp). Bac clones corre-
sponding to the locus are shown underneath
the schematic drawing of chromosome 1
and were derived from C57BL/6 or 129 geno-
mic DNA. Abbreviations: Cen, centromere
and Chr1-H2, chromosome 1 band H2.
(B) Exon-intron structure of the FcγRIV gene.
Exons are shown as black boxes, and repre-
sentative restriction sites are indicated. Ab-
breviations: S, signal sequence; EC, extra-
cellular domain; TM, transmembrane region;
and IC, intracellular tail.evealed the canonical split signal exon of classical FcR
enes, two extracellular domains encoded on separate
xons, and a single exon encoding the transmembrane
nd cytoplasmic domains, features conserved in the
ouse and human FcγRIII α chain genes. In addition,
cγRIV contains a charged amino acid in the putative
ransmembrane domain, a feature shared with FcRs
hat associate with the common γ chain (Bolland and
avetch, 1999). The chromosomal linkage, genomic or-
anization, and sequence characteristics of FcγRIV
oint to a common ancestor for the FcγRIII and FcγRIV
enes and suggest that FcγRIV may share biological
roperties with the FcγRIII gene.
ubunit Composition
o determine the cellular localization and subunit require-
ents for FcγRIV protein expression, cDNAs were iso-
ated for FcγRIV from a spleen library by using DNA
rimers based on the published sequence encoding
his gene. The FcγRIV cDNA was modified with a FLAG
ag at the amino terminus and was transfected into
93T or Chinese hamster ovary (CHO) cells to deter-
ine if surface expression of tagged FcγRIV could be
etected. As shown in Figure 2A, expression of FLAG-
cγRIV was not detected when the isolated chain was
ransfected into 293T cells. In contrast, cotransfection
f FLAG-FcγRIV with a cDNA encoding the common γ
hain resulted in efficient surface expression of FLAG-
cγRIV, detected either by anti-FLAG staining (Figure
A) or by staining with an FcγRIV-specific mAb, 9G8.1,
Figure 2B), thus establishing the requirement for γ
hain coexpression to result in surface expression for
cγRIV, as has been demonstrated for FcγRI and
cγRIII. Coprecipitation studies demonstrated a physi-
al association of γ chain and FcγRIV (Figure S1 avail-
ble in the Supplemental Data with this article online).
chain expression was also required for FcγRIV expres-
ion in vivo, as demonstrated in Figure 2C. FACS analy-
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(A) 293T cells were transiently transfected either with FLAG-tagged mouse FcγRIV (mFcγRIV) alone (left) or additionally cotransfected with an
expression plasmid coding for the common γ chain (mFcγRIV + γ chain). Cells were analyzed 24 hr later by flow cytometric analysis for FcγRIV
cell surface expression with a FLAG epitope-specific antibody (shaded histograms) or an isotype control antibody (open histograms).
(B) Characterization of the FcγRIV-specific monoclonal antibody 9G8.1. Chinese hamster ovary (CHO) cells stably transfected with FLAG-
tagged murine versions of FcγRI, FcγRIIB, FcγRIII, and FcγRIV (mFcγRI, mFcγRIIB, mFcγRIII, mFcγRIV, respectively) were either stained with
the 9G8.1 antibody (top) or a FLAG epitope-specific antibody (anti-FLAG; bottom). Shaded histograms represent the FLAG or FcγRIV antibody
staining, and open histograms indicate the staining with isotype-matched control antibodies. mFcγRI, mFcγRIII, and mFcγRIV were cotrans-
fected with an expression plasmid coding for the common γ chain.
(C) Peripheral blood mononuclear cells were isolated from C57BL/6 wild-type (B6) or C57BL/6 γ chain knockout mice (B6.γ −/−) and stained
with antibodies specific for Mac-1 and FcγRIV (9G8.1). Representative density blots from three independent experiments are shown. Numbers
indicate the percentage of cells in the respective quadrants.
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44sis of peripheral blood cells isolated from either wild- e
otype (wt) or γ chain-deficient mice (γ−/−) stained with
Mac-1, and an anti-FcγRIV-specific monoclonal anti- e
bbody (9G8.1) indicated that the FcγRIV+Mac-1+ popula-
tion is not detected in γ−/− mice. This γ chain depen- m
rdence in vivo was also observed for FcγRI and FcγRIII,
as reported (Takai et al., 1994). o
e
pFcRIV Expression on Cellular Populations
mAb 9G8.1 was used to determine the expression pat- e
ftern of FcγRIV on selective cellular subsets, as shown
in Figures 3A–3D. FcγRIV expression was detected on c
myeloid cells and absent from lymphoid populations.
Peripheral blood monocytes, splenic and bone marrow B
Bdendritic cells, bone marrow, and thioglycollate-elicitedFigure 3. Cell-Type-Specific Expression of
FcγRIV and Cytokine-Mediated Regulation
(A) Peripheral blood mononuclear cells were
stained with antibodies specific for Mac-1,
Gr-1, and FcγRIV. The density plot shows the
Mac-1/Gr-1 staining pattern, and gates iden-
tify Mac-1+/Gr-1− monocytes and Mac-1+/
Gr-1high neutrophils that were analyzed for
FcγRIV expression. Shaded histograms rep-
resent FcγRIV staining, and open histograms
represent staining with an isotype-matched
control antibody. One out of three represen-
tative experiments is shown.
(B) FcγRIV expression on bone marrow-
derived dendritic cells (BM-DCs). Bone mar-
row cells of C57BL/6 mice were cultured in
the presence of GM-CSF for 6 days and
either left untreated (top) or stimulated with
LPS for 24 hr (bottom). Mature dendritic cells
were identified by staining for MHC II (I-Ab),
CD80, CD86, and FcγRIIB/FcγRIII (2.4G2) as
described (Banchereau and Steinman, 1998).
Gates in density plots identify cell popula-
tions that were analyzed for FcγRIV expres-
sion. Shaded histograms represent FcγRIV
staining, and open histograms represent
staining with an isotype-matched control an-
tibody. One out of four representative experi-
ments is shown.
(C) FcγRIV expression on monocytes, mac-
rophages, and neutrophils. Bone marrow-
derived monocytes (BM-Monocytes) were
generated by culturing bone marrow cells for
7 days in the presence of M-CSF. F4/80+
cells were gated and analyzed for FcγRIV ex-
pression. Neutrophils (Mac-1high/Gr-1high) or
macrophages (Mac-1+/F4/80+) were elicited
by intraperitoneal injection of thioglycollate,
collected by peritoneal lavage after 6 hr
(neutrophils) or 4 days (macrophages), and
analyzed for FcγRIV expression (shaded his-
tograms). One out of three representative ex-
periments is shown.
(D) Cytokine-mediated regulation of FcγRIV
expression on BM-Monocytes. Flow cyto-
metric analysis of FcγRIV expression on
M-CSF elicited BM-Monocytes (F4/80+) that
were either left untreated (open histograms)
or stimulated with the indicated cytokines
for 24 hr (shaded histograms). One out of
three representative experiments is shown.macrophages and neutrophils all expressed FcγRIV. Noxpression was observed on T cells, B cells, NK cells,
r other granulocytes (Table 1). Expression of the het-
rooligomeric complex of FcγRIV and the γ chain could
e significantly upregulated on bone marrow-derived
onocytes by interferon-γ (IFN-γ) and LPS and down-
egulated by TGF-β and IL-4 as has been observed for
ther Fc receptors before (Okayama et al., 2000; Pricop
t al., 2001; Tridandapani et al., 2003). The expression
attern of FcγRIV is distinctive among the γ chain-
xpressing FcRs and suggests a more specialized role
or FcγRIV in mediating cellular activation on myeloid
ells.
inding Affinity and Specificity for IgG Subclasses
inding studies on FcγRIV were performed by usingsurface plasmon resonance (SPR) with soluble FcγRIV
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Cell Type Marker/Antibody Origin Expression Levela
B cells CD19 Blood −
Spleen −
Bone marrow −
T cells TCR-β Blood −
Spleen −
γδ-T cells TCR-γδ Spleen −
NK cells NK1.1 Spleen −
Monocytes/macrophages Mac-1high/Gr-1− Blood ++
Mac-1high/Gr-1− Spleen ++
Mac-1high/Gr-1− Bone marrow +
F4/80 M-CSF ++
F4/80/Mac1+ Thioglycollate +++
Dendritic cells CD11chigh/CD8+ or CD8− Spleen +/−b
CD11c+/CD80low/CD86low Bone marrow (DCi) +
CD11c+/CD80high/CD86high Bone marrow (DCm) +/−
Neutrophils Mac-1high/Gr-1high Blood ++
Mac-1high/Gr-1high Spleen ++
Mac-1high/Gr-1high Thioglycollate ++
Other granulocytes Gr-1+/ Mac-1− Blood −
Gr-1+/ Mac-1− Spleen −
Platelets 6A6 antibody Blood −
Expression of FcγRIV on the indicated cell populations from different organs of C57BL/6 mice was analyzed by flow cytometric analysis with
the indicated cell-type-specific markers in combination with the FcγRIV-specific monoclonal antibody 9G8.1. Abbreviations: DCi, immature
dendritic cells and DCm, mature dendritic cells.
a The relative level of expression was compared between different cell types on the basis of the mean fluorescence intensity obtained with
the directly labeled 9G8.1 antibody at different dilutions in three independent experiments.
b Expression was only slightly above background.and a panel of mouse immunoglobulins that were engi-
neered to express the same VH and VL regions and
either the IgG1, IgG2a, IgG2b, or IgG3 constant regions.
These Fc regions were all derived from the C57BL/6
strain and expressed in 293T cells to minimize variation
in allelic difference, antibody glycosylation, or H + L
structure. SPR analysis has been demonstrated to yield
comparable results to classical approaches like analyti-
cal ultracentrifugation or scatchard analysis (Figure S2)
(Ghirlando et al., 1995; Miller et al., 1996; Sondermann
et al., 1999; Mimura et al., 2001). FcγRIV binding to this
series of immunoglobulins was compared to FcγRIIB
and FcγRIII expressed as soluble receptors as de-
scribed for human FcRs (Wines et al., 2000; Maenaka
et al., 2001). FcγRIV bound to IgG2a and IgG2b with an
affinity intermediate between that observed for the low-
affinity receptors FcγRII and FcγRIII and the high-affin-
ity receptor FcγRI. As seen in Figure 4A and Table 2,
FcγRIV binds with an affinity to IgG2a of 3 × 107 (M−1),
an affinity five to ten times greater than IgG2a binding
to FcγRIII or FcγRIIB, respectively. No binding was de-
tected to IgG1 or IgG3. The binding specificity of
FcγRIV was similar when ICs were used to probe CHO
cells expressing FcγRIV + γ chain (Figure 4B). No bind-
ing to FcγRIV was observed when IgM ICs were used
(Figure 4B).
This unique binding specificity of FcγRIV was further
studied in DT40 cells transfected with FcγRIV + γ chain.
Crosslinking of FcγRIV on these cells with IgG2a ICs
resulted in a calcium flux characteristic of FcR signaling
through γ chain (Kurosaki et al., 1992) (Figure 4C). In
contrast, IgG1 complexes were unable to trigger DT40
calcium mobilization, consistent with the undetectable
binding affinity for FcγRIV to IgG1.FcRIV Binding Accounts for the Pathogenic
Activity of IgG2a and IgG2b Antibodies
To determine the in vivo role of FcγRIV in mediating the
biological activity of IgG2a and IgG2b antibodies, we
investigated the ability of a panel of anti-platelet anti-
bodies derived from the 6A6 V region and bearing IgG1,
IgG2a, or IgG2b constant domains to mediate platelet
clearance in intact and FcR-deficient mice. 6A6-IgG2b
induces a rapid thrombocytopenia in wt mice that is
abrogated in γ chain-deficient mice, as shown in Figure
5A, indicating that this antibody is FcR dependent in
its in vivo activity. FcγRI- or FcγRIII-deficient animals,
however, do not exhibit evidence of reduced platelet
clearance in response to 6A6-2b treatment (Figures 5B
and 5C). However, pretreatment of wt mice with a ham-
ster mAb 2C6 specific for FcγRIV and able to block
binding of IgG2a or IgG2b resulted in significant (p <
.001) protection in mice injected with 6A6-2b (Figures
5D and 5E). Moreover, in vivo blocking of FcγRIV activ-
ity resulted in impaired platelet depletion by a 6A6-
IgG2a antibody (Figure 5E). In contrast, 6A6-G1-induced
thrombocytopenia in wt mice was unaffected by pre-
treatment with FcγRIV-blocking antibodies but was
abolished in FcγRIII-deficient mice (Figure 5F). FcγRIV
thus is necessary for the in vivo biological activity of
IgG2a and IgG2b mAbs in their ability to mediate plate-
let clearance, whereas the same platelet specificity
when associated with an IgG1-constant region is FcγRIV
independent and completely dependent on FcγRIII.
Discussion
The immune response has evolved selective pathways
to engage and eliminate the constant threat posed by
Immunity
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(A) Kinetic analysis of FcγRIV binding to C57BL/6 IgG antibody isotypes by surface plasmon resonance. A soluble variant of FcγRIV lacking
the transmembrane and intracellular portions was injected at the indicated concentrations through flow cells containing immobilized antibody
isotypes at a flow rate of 30 l/min. Background binding to flow cells with immobilized BSA was automatically subtracted in all experiments.
(B) Immune complex (IC) binding to FcγRIV. CHO cells stably transfected with mouse FcγRIV (mFcγRIV) and the common γ chain were
incubated with TNP-BSA-biotin/anti-TNP ICs (TNP-ICs) followed by detection of bound TNP-ICs with Pe-Avidin and flow cytometric analysis.
Open histograms represent binding of TNP-BSA-biotin alone, and open shaded histograms represent binding of TNP-ICs.
(C) FcγRIV-mediated IC-triggered calcium release. DT40 cells expressing mFcγRIV and the common γ chain were analyzed for FcγRIV expres-
sion (left). To determine calcium influx mediated by FcγRIV crosslinking, DT40-FcγRIV cells were loaded with Fluo-3 and either left untreated
(broken line) or incubated with IgG1 (thin line) or IgG2a TNP-ICs (thick line). Calcium influx was monitored by flow cytometric analysis.microbial pathogens while preventing these same path- i
aways from triggering unnecessary tissue damage and
systemic disease. This polarization is seen at many r
ilevels of the immune response, from the mechanisms
by which dendritic cells are capable of inducing both k
ptolerogenic and immunogenic response, to the path-
ways that give rise to TH1 or TH2 responses, to the se- n
clective recruitment of specific effector cells elicited in
response to specific pathogens (Sher and Coffman, g
b1992; Steinman et al., 2003). Immunoglobulin isotypes
represent another such example of polarization of the ammune function in response to specific challenges and
re linked to the polarization of TH1 and TH2 cells. TH1
esponses are optimized to facilitate the elimination of
ntracellular pathogens and through the release of cyto-
ines such as IFN-γ result in the activation of macro-
hages and enhance the production of specific immu-
oglobulin subclasses, such as IgG2a and IgG3. TH2
ytokines such as IL-4 and IL-5, on the other hand, are
enerally produced in response to extracellular micro-
ial challenge and lead to enhanced B cell activation
nd the production of IgG1 and IgE and the secretion
FcγRIV: A Novel IgG Fc Receptor
47Table 2. Affinities of Fcγ Receptors for Antibody Isotypes
sFcγRIIB sFcγRIII sFcγRIV
KA (1/M)c KD (M)c KA (1/M)c KD (M)c KA (1/M)c KD (M)c
IgG1 3.33 x 106 3.01 x 10−7 0.31 x 106 3.2 x 10−6 -/-a -/-a
IgG2a 0.42 x 106 2.39 x 10−6 0.68 x 106 1.46 x 10−6 2.9 x 107 3.45 x 10−8
IgG2b 2.23 x 106 4.48 x 10−7 0.64 x 106 1.55 x 10−6 1.7 x 107 5.9 x 10−8
IgG3 −/−a −/−a −/−a −/−a −/−a −/−a
IgG1-D265A −/−a −/−a −/−a −/−a −/−a −/−a
Hu-IgG1 n.d.b n.d.b n.d.b n.d.b 9.6 x 106 1.04 x 10−7
Hu-IgG1-N297A n.d.b n.d.b n.d.b n.d.b −/−a −/−a
Affinity constants were measured by surface plasmon resonance. Soluble versions of murine Fcγ receptors IIb, III, and IV were injected
through flow cells containing the indicated immobilized antibodies at five different concentrations (4, 2, 1, 0.5, and 0.25 g/ml). Background
binding to a reference flow cell containing immobilized BSA was subtracted. IgG1-D265A and IgG1-N297A are mutant IgG1 molecules with
alanin (A) instead of aspartate (D) or asparagin (N) at the indicated position in the Fc portion. Abbreviations: hu, human and sFcγR, soluble
Fcγ receptor.
a −/− indicates no detectable binding.
b n.d. indicates not done.
c The standard deviation for KA and KD was below 5%.FcγRIV, fail to demonstrate IgG2a-mediated protectionpotent subclass in mediating protection. Similarly, in
Figure 5. Analysis of FcγRIV Function In Vivo
(A–C) For analysis of FcγRIV function in vivo,
experimental immune thrombocytopenia was
induced in wt (A), FcγRI−/− (B), and FcγRIII−/−
(C) mice by intravenous injection of 3.5 g
of an IgG2b variant of the 6A6 anti-platelet
antibody (red lines). As a control, platelet de-
pletion in γ−/− mice (g−/−) was included to de-
monstrate FcR dependence (blue lines).
(D) To block IC binding to FcγRIV in vivo,
mice were pretreated with 200 g of an
FcγRIV-specific monoclonal antibody (2C6)
that interferes with IC binding to this Fc re-
ceptor or an isotype-matched control anti-
body, followed by injection with the platelet
depleting 6A6-IgG2b antibody. *p < 0.001;
**p < 0.01.
(E) The percentage of platelet depletion 4 hr
after injection of a 6A6-IgG1, 6A6-IgG2a, or
6A6-IgG2b isotype variant with or without
(mock) previous injection of the 2C6- or 9E9-
blocking antibodies or isotype-matched con-
trol antibodies (Iso) is shown.
(F) Platelet depletion mediated by the 6A6-
IgG1 antibody is FcγRIII dependent. C57BL/6
wt, common γ−/−, and FcγRIII−/− mice were
injected with the 6A6-IgG1 isotype variant,
and platelet counts were followed over time.
Additionally, mice were injected with 200 g
of the FcγRIV-blocking antibody 2C6 or an
isotype control antibody before injection with
6A6-IgG1.
One out of three independent experiments
with five mice per group is shown. For each
group, the mean ± SD was calculated, and
Student’s t test was used for statistical
analysis.of IgA (Mosmann and Coffman, 1989; Finkelman et al.,
1990).
Differential roles for IgG subclasses in host defense
have been studied most extensively for IgG1 and IgG2a
in their ability to confer protection in models of viral and
fungal infection (Coutelier et al., 1987; Schlageter and
Kozel, 1990; Baldridge and Buchmeier, 1992; Markine-
Goriaynoff and Coutelier, 2002; Taborda et al., 2003).
These studies have suggested that IgG2a is the mostmodels of passive antibody-induced cellular depletion,
such as immune thrombocytopenia, hemolytic anemia,
and B cell depletion induced by anti-CD20 antibodies,
IgG2a is the most potent subclass in inducing these
activities (Kipps et al., 1985; Kaminski et al., 1986; Fos-
sati-Jimack et al., 2000; Azeredo da Silveira et al., 2002;
Uchida et al., 2004). Previous studies have shown that
mice deficient in the common FcR γ chain, required for
assembly and surface expression of FcγRI, FcγRIII, and
Immunity
48or pathology, whereas mice deficient in complement C3 c
rdisplay no diminution of IgG2a-induced activity (Clynes
and Ravetch, 1995; Sylvestre et al., 1996; Ravetch and
EClynes, 1998). IgG2a, despite its ability to activate com-
plement through the classical pathway in vitro, medi- M
ates its in vivo activity through Fc receptor activation. C
However, because mice deficient either in FcγRI or H
oFcγRIII retained IgG2a activity, the precise Fc receptor
bresponsible and the basis for the enhanced activity
Hwere not clear. With the identification of FcγRIV, a γ
m
chain-dependent activation FcγR expressed on myeloid t
cells with intermediate binding affinity for IgG2a and w
lIgG2b, a mechanism can be proposed for the enhanced
Yactivity of IgG2a over that observed for IgG1. IgG1
binds exclusively with low affinity (0.3 × 106 M−1) to the
Cactivation receptor FcγRIII, whereas IgG2a binds with C
low affinity (0.7 × 106 M−1) to FcγRIII and with 40-fold A
higher affinity to FcγRIV (2.9 × 107 M−1). It will also bind D
oto FcγRI with high affinity (w1 × 109 M−1). The enhanced
tactivity of IgG2a is thus most easily explained by its
shigher-affinity binding to FcγRIV with additional contri-
(
butions from FcγRIII. The induction of FcγRI and FcγRIV t
expression on macrophages by IFN-γ suggests that TH1 G
wactivation induces both IgG2a expression and its acti-
tvation receptors, thereby amplifying the role of this
wsubclass in mediating effector responses in vivo. IgG2b
6
binds with 10-fold higher affinity to FcγRIV as com- n
pared to FcγRIII, thereby accounting for the preferential w
(role of FcγRIV to the in vivo activity of IgG2b.
BWe have previously demonstrated that the activity of
(IgG1 antibodies in vivo is dependent on the ratio of
o
activation to inhibitory receptor expression (FcγRIII: p
FcγRIIB) (Clynes et al., 2000). Because IgG1 demon- l
strates a 10-fold higher affinity for the inhibitory recep- a
2tor than its activation counterpart, small changes in ex-
(pression of the inhibitory receptor result in pronounced
fchanges in the activation threshold and effector cell re-
s
sponses. In contrast, IgG2a has a 70-fold higher affinity 2
for the activation receptor FcγRIV than the inhibitory
Areceptor FcγRIIB, suggesting that IgG2a activity will be
Aless sensitive to changes in FcγRIIB expression than
NIgG1. Thus, the higher binding affinity of IgG2a to
(
FcγRIV and the reduced affinity to FcγRIIB insure that U
IgG2a functions as a highly effective opsonin to induce I
clearance of pathogens through effector cell activation. m
(In contrast, the preferential binding of IgG1 to the inhib-
sitory receptor may provide a protective mechanism for
Fthis most abundant isotype of serum antibody to pre- M
vent incidental activation of circulating myeloid cells by S
ICs and the systemic inflammation that could follow. F
sThe diversity of cellular receptors for immunoglobu-
Plins mirrors the complexity of responses that are re-
pquired to effectively deal with microbial pathogens.
d
Through the segregation of specific isotypes and sub- h
classes to receptors with distinct cellular distributions, e
iaffinities, and signaling pathways, the selectivity of re-
asponses needed can be provided. Differential regula-
Ttion of these receptors provides yet another level of
w
control, reflecting the polarization of responses to spe- F
cific pathogens. A more complete picture has begun to b
Aemerge with the addition of the FcγRIV to the specifi-ities required to effectively account for the different
oles of immunoglobulin in effective immunity.
xperimental Procedures
ice
57BL/6 mice were obtained from the Jackson Laboratory (Bar
arbor, ME). γ−/−, FcγRII−/−, and FcγRIII−/− mice were generated in
ur laboratory and backcrossed for 12 generations to the C57BL/6
ackground. FcγRI−/− 129/B6 mice were generously provided by Dr.
ogarth (The Austin Research Institute, Victoria, Australia). Female
ice at 2–4 months of age were used for all experiments and main-
ained at the Rockefeller University animal facility. All experiments
ere done in compliance with federal laws and institutional guide-
ines and have been approved by the Rockefeller University (New
ork, New York).
ell Culture and Cell Isolation
HO-K1(CHO), DT40, and 293T cells were cultured according to
TCC guidelines. CHO-FcγRI, CHO-FcγRIII, CHO-FcγRIV, and
T40-FcγRIV stable transfectants were obtained by cotransfection
f the pNTneo-FcγRI, FcγRIII, or FcγRIV plasmids (neomycin resis-
ant) and pNTzeo-γ chain (zeocin resistant) followed by subsequent
election in 1 mg/mL geneticin (Invitrogen) and 0.5 mg/mL zeocin
Invitrogen). The CHO-FcγRII cell line was generated by transfec-
ion of CHO cells with pNT-neo-FcγRII and subsequent selection in
eneticin. Transient expression of FcγRIV alone or in combination
ith the γ chain in 293T cells was achieved by calcium phosphate
ransfection. C57BL/6 bone marrow-derived monocytes (BM-Mo)
ere generated by culturing nonadherent bone marrow cells for
–8 days in DMEM medium supplemented with 10% FBS and 500
g/ml M-CSF (Peprotech). For some experiments, these BM-Mo
ere cultured in medium supplemented with INF-γ (50 ng/ml), LPS
100 ng/ml), TGF-β (100 ng/ml), or IL-4 (100 ng/ml) for 24–36 hr.
one marrow-derived dendritic cells were generated as described
Lutz et al., 1999) and matured by culturing the cells in the presence
f 1 g/ml LPS (Sigma) for 24–48 hr. For flow cytometric analysis,
eripheral blood, bone marrow, and spleen cells were isolated fol-
owed by red blood cell lysis. Thioglycollate-elicited neutrophils
nd macrophages were generated by intraperitoneal injection of
ml of 3% thioglycollate (Sigma). After 6 hr (neutrophils) or 4 days
macrophages), cells were collected by peritoneal lavage and used
or FACS analysis. Neutrophils were identified by their high expres-
ion levels of Mac-1 and GR-1, as described (Ramalingam et al.,
003).
ntibodies
ntibodies 2.4G2, Mac-1, GR-1, CD19, TCR-β, TCR-γδ, CD11c,
k1.1, CD80, CD86, and I-Ab were purchased from Pharmingen
San Diego, CA). The F4/80 antibody was from Serotec (Oxford,
K). The TNP-specific mouse antibodies IgG1,λ (clone 107.3),
gG1,κ (clone A111-3), and IgM (clone G155-228) were from Phar-
ingen. The TNP-specific mouse IgG2a (clone 7B4) and IgG2b
clone 1B4) were kind gifts from Dr. B. Heyman (Uppsala Univer-
ity, Uppsala, Sweden). Fluorescein isothiocyanate (FITC)-labeled
(ab#)2 goat anti-hamster IgG and DNP-specific IgG3 (clone
ADNP-4) were purchased from Serotec, FITC anti-FLAG from
igma, phycoerythrin (PE)-F(ab#)2 anti-mouse Fab-specific, and
ITC goat anti-armenian hamster IgG from Jackson Immunore-
earch (West Grove, PA). Neutravidin-PE was from Molecular
robes (Eugene, OR). For Biacore analysis and in vivo platelet de-
letion experiments, C57BL/6 IgG isotype variants of 6A6 were pro-
uced by transient transfection of 293T cells with Fc-engineered
eavy chains and the native light chain, as described (Wardemann
t al., 2003), and subsequent purification of recombinant antibod-
es from serum-free culture supernatants via protein A or protein G
ffinity columns (Amersham) as suggested by the manufacturer.
he human IgG1 and IgG1-N297A (nonglycosylated) antibodies
ere kindly provided by Dr. Stavenhagen (Macrogenics, Inc.).
cγRIV-specific antibodies were produced at the monoclonal anti-
ody facility of the Memorial Sloan Kettering Cancer Center. Briefly,
rmenian hamsters were injected with an FcγRIV-IgG1 fusion pro-
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49tein consisting of the extracellular domain of FcγRIV fused to a
mouse IgG1 Fc portion (D265A-variant deficient in Fc-receptor
binding) kindly provided by S. Burke (Macrogenics, Inc.). After im-
munizations and boosting, hamster splenic B cells were fused to
a mouse fusion partner, and hybridoma clones were selected for
secreting antibodies that bound to CHO-K1-FcγRIV cells express-
ing mFcγRIV in a flow cytometric assay. In this study, three of these
clones, 9G8.1, 2C6, and 9E9, were used. In contrast to 9G8.1, the
2C6 and 9E9 antibodies interfere with IC binding to FcγRIV. The
2C6 antibody shows crossreactivity to FcγRI but does not interfere
with IC or monomeric antibody binding to this receptor (data not
shown). Both of these antibodies were purified from hybridoma su-
pernatants by protein G affinity chromatography. For FACS analy-
sis, the 9G8.1 antibody was directly labeled with the Alexa 488 or
Alexa 647 dyes (Molecular Probes) as suggested by the manufac-
turer.
IC Binding Assay
ICs were preformed by incubating biotinylated BSA-(5)-TNP at 10
g/ml with anti-TNP/DNP monoclonal antibodies at 15 g/ml for 1
hr at 37°C in PBS. 2 × 105 cells were incubated with these ICs
for 2 hr at 4°C. After washing, bound ICs were detected by using
Neutravidin-PE at 2 g/ml for 1 hr at 4°C, followed by washing and
flow cytometric analysis using a FACSCalibur cytometer (Becton
Dickinson).
cDNA and Cloning
The FcγRIV cDNA was amplified from C57BL/6 spleen cDNA by
PCR using the primers FcγRIV-forward (5#-ATCTGCTCTAGAAGC
ATGTGGCAGCTACTA-3#) and FcγRIV-reverse (5#-CATGCGATAAGA
GCTCACTTGTCCTGAGGT-3#). DNA sequencing revealed a com-
plete match to the Ensembl database sequence (http://www.ensembl.
org). cDNA coding for mFcγRIIB1 (Ly17.2 haplotype), mFcγRIII, and
γ chain was previously cloned in the laboratory, mFcγRI cDNA was
a kind gift from B. Seed. To enable cell surface detection, a FLAG
epitope tag was inserted immediately 3# of the signal sequence
cleavage site in mFcγRI, mFcγRII, mFcγRIII, and mFcγRIV by PCR
using overlapping primers. Resulting constructs were cloned into
pNT NEO (a gift from M. Daëron). For the generation of soluble
variants of FcγRII, FcγRIII, and FcγRIV, the extracellular domains of
FcγRII (amino acids 1–211), FcγRIII (amino acids 1–216), and FcγRIV
(amino acids 1–201) were amplified by PCR and cloned in frame
with a C-terminal hexahistidine or FLAG epitope tag at the C termi-
nus into pcDNA3.1. The 6A6-antibody heavy and light chains were
cloned out of the parental hybridoma by using a 5#RACE approach
(Invitrogen). After sequencing individual clones, the most abundant
sequences similar to known antibody heavy and light chain se-
quences were fused to the Fc portions of IgG1, IgG2a, and IgG2b
derived from C57BL/6 mice (kindly provided by Dr. Fukuyama,
Rockefeller University, New York, NY), expressed by transient
transfection in 293T cells, and tested for their ability to deplete
platelets (see below).
Production of Soluble Mouse Fc Receptors
Soluble Fcγ receptors and recombinant antibodies were generated
by transient transfection of 293T cells with calcium phosphate
transfection. For protein production, cells were cultured in DMEM
medium supplemented with 1% Nutridoma SP (Roche). Cell culture
supernatants were harvested 6 days after transfection, and recom-
binant proteins were purified with Ni-NTA (Qiagen) or anti-FLAG
agarose (Sigma) by affinity chromatography. All proteins were dia-
lyzed against PBS and further purified by gel filtration (Amicon
Ultra, Millipore). Purity was assessed by SDS-PAGE followed by
Coomassie blue staining and was estimated to be greater than
90%.
Gene Mapping
C57BL/6 genomic DNA BAC clone libraries (IncyteGeomics) were
screened by using the 32P-labeled cDNA encoding the first extra-
cellular domain of mFcγRIV as a probe. Positive clones were found
to be the same as the ones positive for murine FcγRIIB and/or mu-
rine FcγRIII genes. Precise gene mapping for FcγRIV was done byusing restriction enzyme digestion, followed by southern blot
analysis using additional probes corresponding to the 5# and the
3# regions of each FcγR murine gene to determine gene orientation.
Results found were crosschecked by multiple alignments (Meg-
Align: DNAstar, Lasergene) using our cDNA and BAC clone se-
quencing results and the mouse Ensembl database sequences for
mouse chromosome 1: the FcγRIV gene mapping and orientation
corresponds to the Ensembl gene NM_144559 but differs from the
results Mechetina et al. (2002) for positioning and orientation.
Flow Cytometric Analysis of Ca2+ Mobilization
The intracellular-free calcium concentration was determined by
preloading 1 × 106 DT40 cells with 5 mM Fluo-3 AM (Molecular
Probes, Eugene, OR) in the presence of 0.2% Pluronic F-127
(Sigma, St. Louis, MO) for 30 min at room temperature. Cells were
washed three times in RPMI 1640 and resuspended at 1 × 106 cells/
ml in complete medium, followed by incubation with IgG1 or IgG2a
ICs as described above; the intracellular-free calcium concentra-
tion was monitored with a flow cytometer. The mean [Ca2+]i was
evaluated with FCS assistant 1.2.9 b software (Becton Dickinson).
SPR Analysis
A Biacore 3000 biosensor system was used to assay the interaction
of soluble Fcγ receptors II, III, and IV with the indicated antibody
isotypes. Antibodies or BSA as a control protein were immobilized
at high and low densities to flow cells of CM5 sensor chips (Bia-
core) by standard amine coupling as suggested by the manufac-
turer. Soluble Fcγ receptors were injected at five different concen-
trations through flow cells at room temperature in HBS-EP running
buffer (10 mM Hepes, [pH 7.4], 150 mM NaCl, 3.4 mM EDTA, and
0.005% surfactant P20) at a flow rate of 30 l/min. Soluble Fc re-
ceptors were injected for 3 min, and dissociation of bound mole-
cules was observed for 15 min. Background binding to control flow
cells was subtracted automatically. Control experiments were per-
formed to exclude mass transport limitations (data not shown). Af-
finity constants were derived from sensorgram data by using simul-
taneous fitting to the association and dissociation phases and
global fitting to all curves in the set. As described for soluble hu-
man Fc receptors, a 1:1 Langmuir binding model closely fitted the
observed sensorgram data and was used in all experiments (Mae-
naka et al., 2001). Alternatively, soluble Fc receptors were immobi-
lized to sensor chips with the same result described above.
Experimental Immune Thrombocytopenia
Mice (2–4 months) were injected intravenously with 3.5 g of the
recombinant 6A6-IgG2b variant diluted in 200 l of PBS. Alterna-
tively, mice were injected with 5.5 g of the 6A6-IgG1 antibody
variant. As described before, for other antibody switch variants (Az-
eredo da Silveira et al., 2002) the IgG1 isotype proved to be less
efficient in mediating platelet depletion and had to be injected at a
slightly higher dose. Platelet counts before injection and at indi-
cated time points after injection were determined by blood collec-
tion (40 l) from the retro-orbital plexus and measuring platelet
counts of a 1:10 dilution in PBS/5%BSA in an Advia 120 hematol-
ogy system (Bayer). Alternatively, mice were injected 30 min before
administration of the 6A6 antibody variants with 200 g of the
blocking FcγRIV antibodies 2C6 or 9E9 or with 200 g of hamster
isotype control antibodies (Pharmingen).
Supplemental Data
Supplemental Data include three figures and are available with this
article online at http://www.immunity.com/cgi/content/full/23/1/41/
DC1/.
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